Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo gains generic cough-suppressant rights

This article was originally published in The Tan Sheet

Executive Summary

Perrigo acquires exclusive U.S. private label rights to a generic version of Reckitt Benckiser's Delsym cough suppressant through a partnership with the specialty pharmaceutical company Tris Pharma. The partnership is a profit-share deal, with Perrigo making milestone payments to Tris, Perrigo said May 5. Tris said it is the first to file an abbreviated new drug application for dextromethorphan polistirex extended-release suspension, which would entitle it to 180 days of generic exclusivity upon approval. Tris and Reckitt currently are litigating the filing. Delsym, indicated for 12-hour cough relief, generates estimated annual sales of $125 million, according to data from SymphonyIRI Group. In a May 5 note, investment firm Collins Stewart says the deal "adds more visibility to future earnings growth" for Perrigo beginning in 2012. "We would expect [Perrigo] to continue to add product opportunities like Delsym to its pipeline," Collins Stewart says
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS104093

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel